EMA Recommends Granting a Marketing Authorisation for Tarlatamab By Ogkologos - April 17, 2026 282 0 Facebook Twitter Google+ Pinterest WhatsApp It is indicated for the treatment of adult patients with extensive-stage SCLC Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR First Global Estimates of Cervical Cancer Attributable to HIV November 30, 2020 Waiting for Insurance to Cover Her Mammogram Could Have Cost This... April 9, 2019 Magnetic Fish-Shaped Microbots Deliver Chemotherapy to Exactly Where It’s Needed December 9, 2021 Niraparib Plus Abiraterone Acetate and Prednisone Improves rPFS and Other Clinically... August 8, 2023 Load more HOT NEWS EMA Recommends Extension of Indications for Trastuzumab Deruxtecan to Include Treatment... Tarlatamab Shows Promise for Some People with Small Cell Lung Cancer Routes to a healthier shopping journey – how your supermarket environment... Many Patients with NSCLC Show Targetable Alterations in the PI3K Pathway
